Targeted immunotherapy at the CCCZ

At the CCCZ, we use targeted immunotherapies to enable the body's own immune defenses to recognize tumor cells and eliminate them in a targeted manner.

Our immune system

The human immune system protects the body from damage caused by infectious diseases by recognizing “invaders” as foreign and repelling them, but at the same time preserving healthy tissue or allowing it to regenerate. First of all, cancer is the body’s own tissue, i.e. it is not fundamentally foreign. However, this carries genetic changes that trigger the uncontrolled growth and do not occur in this way in healthy tissue. However, these changes are often “hidden”, do not show up sufficiently on the tumor cell surface, and increase only slowly in type and quantity. This then leads to the fact that the tumors are very similar to healthy tissue and that the patient’s own immune system either cannot recognize the changes at all and is not activated. Or the change is detected but the immune response is suppressed, meaning that a kind of tumor immune tolerance occurs. The result is an absent or insufficient immune response and thus a growing tumor.

What is immunotherapy?

Tumor immunotherapy” is an umbrella term for very different approaches that use the body’s own immune system as an ally in the fight against cancer.

Targeted immunotherapies are directed against specific molecules on the surface of cancer cells and thus have a more specific effect than classical chemotherapies. These therapies represent important steps in the direction of harming only the tumor, if possible, and sparing the healthy, vital tissue.

What are the types of immunotherapy?

Immunotherapies can be either externally administered immunotherapeutics (e.g. antibodies against tumor cells, which are not normally produced by the body in this way) or, in the case of a shutdown of the patient’s own immune system, it can be activated by loosening the “brakes” of the immune system, so to speak, and thus lifting the immune tolerance.

Checkpoint Inhibitors

In the type of immunotherapy that aims to release the brakes on the patient’s own immune system, we aim to strengthen the existing but inactive immune response so that it fights the cancer. The immune response is based on the fact that cancer cells may have a tumor antigen on their surface, i.e., they carry a surface feature that is different from healthy tissue. This allows the tumor cell to be perceived by the immune system as a type of foreign cell. Some tumors have many of these different surface features, while others have few of them. In addition, tumors can also produce specific “brake molecules” for the immune system. It is interesting and logical that immune activation therapy of the patient’s own immune system usually works well precisely in those patients whose tumors carry many different surface features and many of these braking molecules compared to healthy tissue. By overriding the braking or control signal – the substances are also called “checkpoint inhibitors” – an immune response against the tumor then occurs.

A side effect of this activating immunotherapy can be that the brakes of other immune cells are also released and thus side effects occur that correspond to autoimmune diseases, i.e. that the immune system attacks healthy tissue as well. So there is a problem of selectivity here. However, depending on the type of cancer, the resulting side effects can be accepted and in some cases well controlled. Overall, one can assume fewer and different side effects than with classical chemotherapy.


In addition to the above-mentioned activation of the patient’s own immune system, there are immunotherapies in which structures of the immune system are produced externally. These are then infused. The simplest and classic example is so-called antibodies, which go to tumor cell surfaces and attack them. Either the targets of the antibodies are tumor-specific (this is rare) or the targets are also present on healthy tissues but in lower density, or the tissue can be temporarily dispensed with and it regenerates after therapy.

Artificial antibody constructs

Recent developments in so-called “designer immunology” show that it is also possible to produce antibodies or antibody fragments to which one can then couple either chemotherapy or radiotherapy or cell messengers and deliver them relatively selectively to the tumor. Similarly, antibodies can be produced that act as an activating bridge between the tumor cell and the body’s own immune cell. That is, these antibodies stimulate the immune cell to kill the tumor cell.

CAR T cells

Another development is the genetic manipulation of the body’s own immune cells. In this way, antibodies can be introduced into “killer cells” so that they then attack the tumor cells with high selectivity. These include, for example, the so-called Chimeric Antigen Receptor (CAR) T cells.

For CAR T-cell therapy, white blood cells – so-called T lymphocytes – are taken from patients’ blood. These are then genetically modified in the laboratory so that they can recognize cancer cells. The optimized T lymphocytes are then administered back to patients via an infusion to target and destroy cancer cells. This type of therapy is only offered at a few, highly specialized centers in Switzerland.

Manuel Schibli also benefited from the new possibilities of targeted immunotherapy. The 25-year-old from the canton of Aargau was diagnosed with acute lymphoblastic leukemia (ALL), a relatively rare cancer in adults. This specific form of blood cancer can be treated with CAR-T cells since a few years.

The story of Manuel Schibli


In the field of immunotherapy (checkpoint inhibitors, antibody engineering, CAR-T cells), we conduct innovative research at the CCCZ. For example, we are investigating new immunotherapeutic treatment concepts within the Clinical Research Focus (KFSP) of the UZH “ImmunoCure” and in the University Medicine Zurich project “ImmunoTargET” with the aim of establishing a platform for targeted tumor immunotherapy in Zurich.

ImmunoCure Immuno-TargET

Our offer

All of the above immunotherapy methods are currently already being used clinically at CCCZ for various tumor diseases.


At the Comprehensive Cancer Center Zurich, organ centers work together on an interdisciplinary basis. In this way, we bundle the knowledge of all experts for the respective tumor types and cancer diseases. Appointments and inquiries about treatment options can be made directly to our organ centers.

To the organ centers

For patients

As a patient, you cannot register directly for a consultation. Please get a referral from your primary care physician, specialist. For questions please use our contact form.

Contact form

For referrer

Comprehensive Cancer Center Zurich
University Hospital Zurich
Rämistrasse 100
8091 Zurich

Tel. +41 44 255 44 00